NK cells are capable of receptor-mediated lysis of target cells that lack self class I MHC molecules. Thus, it is possible that they can be used effectively in an MHC I mismatched allogeneic BMT to create myeloablation without developing GVHD. We wanted to define the role of the NK cell as a myeloablative agent. C57Bl/6 (B6) adult NK cells were injected i.p. into 2 day old Balb/c newborns. At various times post transplant, bone marrow was harvested and in-vitro colony forming assays were done. We found that allogeneic NK cells destroyed both erythroid and myeloid progenitor cells by 5 days post injection with some recovery by 19 days. We then injected NK cells with/without bone marrow from C57Bl/6 (B6) mice into 14 day old Balb/c fetuses and newborn animals. We found that none of the fetal recipients survived the in utero transplants even when the number of NK cells was reduced to 10,000 cells. Histologic studies suggested severe liver toxicity associated with the fetal injections. In contrast, 7/10 newborn recipients of allogeneic lin Ϫ BM and NK cells had multi-lineage engraftment 8 weeks post transplant (Table) . The engraftment was inhibited by co-administration of anti NK1.1 mAb or anti-TGF beta antibody suggesting that NK cells play a role in the engraftment and mediate their effect at least partially through the secretion of TGF-beta. We used an Artemis deficient T Ϫ B Ϫ NK ϩ mouse to study the repopulation of the marrow following transplant with NK cells. We found significant repopulation of T cells (36 Ϯ 17% vs 7 Ϯ 2% control) in blood and thymus with evidence of B cell reconstitution in bone marrow. NK cells can be used effectively as a means of enhancing donor cell engraftment and in some circumstances inducing multilineage engraftment. This work was supported by a grant from the NIH NIAID RO1 HL58842 (Table 1) . We analyzed infections occurring beyond 6 months after allo-SCT, in 81 consecutive pts who received a RIC prior to allo-SCT from HLA-identical siblings: median age was 49 (18 -63) years. 33 (41%), 34 (42%) and 14 (17%) pts had respectively a myeloid, lymphoid or non-hematological malignancy. 62 pts (77%) had an advanced disease with high risk clinical features precluding the use of standard myeloablative allo-SCT. 21 pts (26%) BMT and 60 (74%) PBSCT. RIC consisted of fludarabine and busulfan with ATG (high dose: 20 (25%); low dose: 50 (62%)) or of low dose irradiation-based RIC (Nϭ11, 13%). With 26 (9 -68) months follow-up, 67 pts (83%) experienced at least one infectious episode beyond the first six months after allo-SCT developing at a median of 8 (6 -34) months. 221 infectious episodes were observed, of which 123 (56%) required hospitalization and systemic anti-microbial therapy. 94 episodes (43%) could be documented (bacterial, nϭ28; viral, nϭ56; fungal, nϭ10) . Documented infections were: gram negative bacteria (16%), other bacteria (14%), CMV positive antigenemia (17%), HSV (25%), VZV (15%), other viruses (3%), aspergillus (4%), candida species (6%). 81% pts (nϭ54) with an infection were under systemic immunosuppressive therapy for chronic GVHD. Moreover, 24 pts (30%) experienced Ͼ1 episode of documented infections (median, 2 episodes; range, 1-12). In a univariate analysis performed in the pts with documented infection, age Ͻ50 (Pϭ0.06), the use of PBSCs as stem cell source (Pϭ0.03) and a history of DLI (Pϭ0.002), exerted a protective effect against infection occurrence. In a multivariate analysis, DLI was significantly associated with a decreased risk of long term infections (Pϭ0.002; RRϭ0.23; 95% CI, 0.1-0.6), indirectly highlighting the protective effect of donor origin immunity after allo-SCT. In this series of pts surviving at least 6 months after RIC allo-SCT, the overall long term transplant-related mortality was 14% (nϭ11), of whom 6 deaths were attributed to infections (3 bacterial septicemia, 2 aspergillosis, 1 pneumocystosis), giving a cumulative incidence of long term-infectious related mortality of 7% (95% CI, 1.4 -12.6%). Obviously, prospective efforts to develop optimal antimicrobial preventive strategies after RIC allo-SCT are still needed. However, the results from this analysis compare favorably with data from the standard myeloablative allo-SCT setting. Heilmann, C.; Laursen, H.B.; Muller, K.; Haastrup, E.; Jacobsen, N. BMT Unit, Rigshospitalet, University Hospital, Copenhagen, Denmark. Background: During recent years it has been the impression in many centres that TRM following allogeneic stem cell transplants has declined significantly. This impression has been strong in our centre as well. The aim of the present study was to analyze the magnitude of this presumed reduction in procedure related risks and to examine possible causes. Method: We analyzed a recent time period of ten years from Jan. 1994 to Jan. 2003. Non myeloablative transplants were excluded from the study. During this period 224 and 219 standard allotransplants were performed during the first and the second 5-year time periods respectively. All transplants were performed at the same centre (Copenhagen, Denmark), whose organization has essentially remained the same for the whole time period. Results: TRM differed significantly (pϽ0.0001) between the two time periods. The one-year Kaplan-Meier based TRM declined from 33.5% to 13.9%. On the basis of univariate analysis no significant differences was found between the compositions of the main diagnosis (AML, ALL, MDS, CML, non-malignant). Likewise, when the pre-transplant stages of acute leukaemia and CML were compared between the two periods non differences were recorded, except that slightly less very high risk ALL patients were transplanted during the last period. No difference in age distribution was found. In contrast, a tendency for a more restrictive donor selection policy could be recorded. Hence, the composition of donor types (HLA-id Sib vs. other fam. donors vs. UD; pϭ0.007), donor gender (less female to men; pϭ0.018) and the use of class I high-resolution donor typing for UD (pϭ0.0001) Poster Session I changed between the two time periods. Also, the use of PBSC instead of BMSC increased (Pϭ0.0001). In order to evaluate the relative importance of these factors a multivariate analysis will be performed. Conclusion: The pronounced improvement in TRM during recent years seem to be multi factorial however, an improved donor selection strategy is probably the main cause. Claxton, D.F.; Ehmann, C.; Shaffer, M.; Rybka, W. Penn State College of Medicine, Hershey, PA. Non-myeloablative regimens extend the benefit of allogeneic hematopoietic transplantation to many otherwise ineligible patients. Anti-tumor effects are however thought not to occur for most patients until full donor chimerism is achieved. We have recently added sirolimus to an established conditioning regimen in an attempt to optimize engraftment and anti-tumor effects while minimizing morbid GVHD. We compare results of two sequential studies conditioning patients with hematological malignancies with cyclophosphamide (days Ϫ7 and Ϫ6) and fludarabine (days Ϫ7 through Ϫ3) prior to matched sibling peripheral blood stem cell transplantation. All received tacrolimus and methotrexate immunoprophylaxis. 9 patients were enrolled in the initial study, and 6/9 also received Campath 1H 20 mg IV on day Ϫ7 of the regimen. The second study has treated 10 patients with sirolimus added to the immunosuppression and adjusted to 5-15 ng/ml beginning on day Ϫ7 (no Campath was given on this study). Tacrolimus has been tapered off in this protocol between days 30 -45, but sirolimus has continued. Graft versus host disease occurred prior to day 100 in 5/9 patients on protocol 1 and 2/10 patients on protocol 2. In all cases GVHD was controllable and no patient has died of transplant related causes. In both protocols all patients showed some degree of donor engraftment by RFLP or XY FISH analysis by day 30. Mean fractional peripheral blood donor chimerism values through day 180 are given in the table below. There is no significant interaction between treatment and time (p-valueϭ0.8579), hence the engraftment curves for the two protocols are parallel. Based on a repeated measures analysis using general F-statistics, there is a significant treatment effect, with patients on the second protocol showing an average of 18% higher engraftment (p-valueϭ0.0281). While follow-up is shorter for patients on Protocol 2, 8/10 patients are beyond 180 days from transplant and the other two have both achieved Ͼ0.98 fractional donor engraftment. We conclude that our second protocol, using sirolimus with early tapering of tacrolimus, appears to yield more rapid and complete donor chimerism (Table) . Soydan, E.; Civriz, S.; Beksac, M.; Koc, H.; Gurman, G.; Ilhan, O.; Arat, M Ankara University Medical School Department of Hematology, Ankara, Turkey.
Engraftment (Percent) in Newborn Balb/c Recipients of B6 NK Cells and Lin Ϫ Bone Marrow at 8 Weeks

DRAMATIC CHANGE IN TREATMENT RELATED MORTALITY (TRM) FOR ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) DURING RECENT YEARS. A ONE CENTRE ANALYSIS
IMPROVEMENT OF MATCHED SIBLING DONOR ENGRAFTMENT WITH SIROLIMUS ADDED TO A NON-MYELOABLATIVE CONDITIONING REG-IMEN
Donor Fractional Whole Blood Chimerism
IMATINIB ONLY FOR MOLECULAR RELAPSE IS NOT SUFFICIENT TO ACHIEVE A DURABLE COMPLETE CHIMERIC STATUS AND MOLECULAR REMISSION AFTER ALLO HCT IN CML
Background: Allogeneic hematopoietic cell transplantation (Al-loHCT); today, is still the only treatment modality that provides cure for CML. But relapses after AlloHCT are still an ongoing problem. In most of these patients donor lymphocyte infusions (DLI) are effective to achieve molecular remission (MR). Post DLI aplasia and GVHD are the most important reasons of morbidity and mortality in these patients. Imatinib is a tyrosine kinase inhib-itor and blocks CML progenitor cell proliferation. The effect of imatinib on relapse after AlloHCT has been investigated in a few studies including patients with chronic and accelerated phase CML. In this study we aimed to analyze the effect of imatinib on post AlloHCT molecular relapse. Patients and Method: Imatinib was applied 400 mg/day p.o. at least for six months to 11 patients; transplanted from their HLA identical siblings with molecular relapse. Patients were monitored closely with ATM Multiplex PCR for chimerism and RQ-PCR (LightCycler, Roche Diagnostics) for bcr-abl/G6PDH. Results: Eleven of the patients were under imatinib treatment for more than 6 months. Seven of the 11 patients responded to imatinib. At the end of the sixth month except two patients all of them had donor type chimerism. Periorbital edema developed in 4 of the patients, and none of the patients had Gr 3-4 GIS and hematologic side effect. After cessation of the drug five patients had durable MR and complete chimeric (CC) status. Two patients with second molecular relapse and mix chimeric status after imatinib, and four patients with primary imatinib resistance received DLI. After median 12 (6 -20) months follow up, imatinib sensitive 5 patients were in continuing MR, imatinib sensitive two patients with second relapse were in MR and CC after DLI. One of the imatinib refractory patients was lost after DLI induced acute GVHD in MR, The remaining patients did not achieve MR. One patient is still receiving DLI, IFN and imatinib. Conclusion: Imatinib treatment for molecular relapse after AlloHCT has acceptable adverse event profile and provides over 60% MR rate but this response was not durable as in DLI; 25% of the patients experience second relapse early after cessation of the drug. DLI may achieve MR in 50% of the primary imatinib resistant patients. Concerning the in vitro effect if imatinib on T cell functions there is an urgent need for prospective studies comparing DLI and imatinib Ϯ DLI with close follow up of chimerism.
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